585-49-9

Upstream product

• 98-17-9 3-Trifluoromethylphenol 
• 106-95-6 allyl bromide 

Downstream Products

• 585-43-3 2-allyl-5-trifluoromethyl phenol 
• 41389-17-7 2-allyl-5-(trifluoromethyl)phenol 
• 98-17-9 3-Trifluoromethylphenol 
• 902261-47-6 3-(3-trifluoromethyl-phenoxy)-propane-1,2-diol 
• 61761-32-8 5-fluoronaphthalen-1-ol 
• 1629184-55-9 2-(allyloxy)-1-propyl-4-(trifluoromethyl)benzene 
• 1629184-56-0 2-allyl-6-propyl-3-(trifluoromethyl)phenol 
• 325-36-0 2-allyl-5-trifluoromethyl-anisole 
• 582-14-9 2-propyl-5-trifluoromethyl-anisole 
• 618-05-3 2-propyl-5-(trifluoromethyl)phenol 
• 448-36-2 2-methoxy-4-(trifluoromethyl)-benzoic acid 

Relevant academic research and scientific papers

A mild and practical method for deprotection of aryl methyl/benzyl/allyl ethers with HPPh2andtBuOK

A general method for the demethylation, debenzylation, and deallylation of aryl ethers using HPPh2andtBuOK is reported. The reaction features mild and metal-free reaction conditions, broad substrate scope, good functional group compatibility, and high chemical selectivity towards aryl ethers over aliphatic structures. Notably, this approach is competent to selectively deprotect the allyl or benzyl group, making it a general and practical method in organic synthesis.

Reduction of C,O-chelated organotin(IV) dichlorides and dihydrides leading to protected polystannanes

A series of aryloxy organotin compounds Ph3Sn(CH2)3OC6H4R (5: R = H; 6: R = Ph; 7: R = OCH3, 8: R = CF3), Ph2ClSn(CH2)3OC6H4R (9: R = H; 10: R = Ph) and PhCl2Sn(CH2)3OC6H4R (12: R = H; 13: R = Ph) have been synthesized and characterised by NMR (1H, 13C, 119Sn) spectroscopy. X-ray structure determinations of 9, 10, 12 and 13 reveal a distorted trigonal bipyramidal geometry at Sn with Cl trans to the datively bonded O whereas 8 possesses tetrahedral geometry and a Sn? dative interaction is absent. Triorganotin hydrides Ph2HSn(CH2)3OC6H4R (14: RH; 15: RPh) and diorganotin dihydrides PhH2Sn(CH2)3OC6H4R (16: RH; 17: RPh) were prepared by reduction of the corresponding dihalides with LiAlH4. Catalytic dehydrocoupling of dihydrides 16 or 17 with a late transition metal catalyst afforded asymmetrical hypercoordinated polystannanes [PhSn(CH2)3OC6H4R]n (18: RH; 19: RPh) with relatively high molecular weights (Mw 1.3 104 e 2.5 105 Da) and narrow polydispersities (PDI's 1.3e3.3). NMR and UVeVis spectroscopy studies indicate that the new polymers display dramatically improved light stability, but remain sensitive to moisture.

A transition-metal-free synthesis of fluorinated naphthols

Herein, we describe a transition-metal-free protocol for the conversion of simple 2-allyl-3-(trifluoromethyl)phenols into substituted 5-fluoronaphthalen-1- ols. The key events of this reaction include the selective activation of two C-F bonds and formatio

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

Process for the Preparation of Prostaglandin Analogues and Intermediates Thereof

The present application provides intermediates for preparing prostaglandin analogues and processes for preparing prostaglandin analogues and intermediates thereof. The intermediates include: A compound of formula (6): R1 represents H, C1-C5-alkyl, or benzyl, in particular isopropyl.

BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

Compounds of formula (I); which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).